Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.

Oncology reports - 1 Sept 2005

Noma Kazuhiro, Naomoto Yoshio, Gunduz Mehmet, Matsuoka Junji, Yamatsuji Tomoki, Shirakawa Yasuhiro, Nobuhisa Tetsuji, Okawa Takaomi, Takaoka Munenori, Tomono Yasuko, Hiroyuki Ohmori, Gunduz Esra, Tanaka Noriaki

Abstract excerpt

Mutations of proto-oncogene c-kit in gastrointestinal stromal tumors (GISTs) are considered to cause a constitutive activation of KIT responsible for their oncogenesis. Imatinib has therapeutic potential for GISTs because of its inhibitory effect on KIT kinase activity. However, no study has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Caspases
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins c-kit

Source

Identifiers

PMID: 16077968

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16077968-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.PMID 16077968Read ↗

Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.Semantic proximity Read ↗

[Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].Semantic proximity Read ↗

[Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].Semantic proximity Read ↗

In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Significant antitumor effectiveness of imatinib in c- kit negative gastrointestinal stromal tumor - case report.Semantic proximity Read ↗

[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].Semantic proximity Read ↗

The c-KIT Exon 11 Deletions Cause Resistant to Imatinib Treatment of GISTs through Induction of ULK1-SRC related AutophagySemantic proximity Read ↗

Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.Semantic proximity Read ↗

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genesSemantic proximity Read ↗

Secondary mutations in the kinase domain of the <i> KIT</i> gene are predominant in imatinib‐resistant gastrointestinal stromal tumorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.